Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 399

1.

Endothelium, atherosclerosis and calcium channel blockers.

Biswas TK.

J Indian Med Assoc. 2003 Jul;101(7):428-31.

PMID:
14748381
2.

Calcium channel blockers, endothelial dysfunction, and combination therapy.

Schulman IH, Zachariah M, Raij L.

Aging Clin Exp Res. 2005 Aug;17(4 Suppl):40-5. Review.

PMID:
16640172
3.

Calcium antagonists and atherosclerosis protection in hypertension.

Hernández RH, Armas-Hernández MJ, Velasco M, Israili ZH, Armas-Padilla MC.

Am J Ther. 2003 Nov-Dec;10(6):409-14. Review.

PMID:
14624278
4.

Effects of antihypertensive drugs on endothelial dysfunction: clinical implications.

Taddei S, Virdis A, Ghiadoni L, Sudano I, Salvetti A.

Drugs. 2002;62(2):265-84. Review.

PMID:
11817973
5.

[Calcium antagonists and endothelial function].

Yasuda O, Kawamoto H, Yokoi T, Rakugi H, Ogihara T.

Clin Calcium. 2005 Oct;15(10):1663-8. Review. Japanese.

PMID:
16199912
6.

Targeting endothelial dysfunction in hypertensive subjects.

Thuillez C, Richard V.

J Hum Hypertens. 2005 Jun;19 Suppl 1:S21-5. Review.

PMID:
16075029
7.

Optimal vascular protection: a case for combination antihypertensive therapy.

Vogel RA.

Prev Cardiol. 2006 Winter;9(1):35-41. Review.

8.

Antihypertensive therapy and endothelial function.

Nadar S, Blann AD, Lip GY.

Curr Pharm Des. 2004;10(29):3607-14. Review.

PMID:
15579057
9.

Endothelial dysfunction and hypertension.

Ferro CJ, Webb DJ.

Drugs. 1997;53 Suppl 1:30-41. Review.

PMID:
9034753
10.
11.

Endothelial factors and microvascular hypertensive disease.

Rizzoni D, Agabiti-Rosei E.

J Cardiovasc Pharmacol. 2001 Nov;38 Suppl 2:S15-8.

PMID:
11811369
12.
13.

A rationale for treatment of endothelial dysfunction in hypertension.

Ruschitzka F, Corti R, Noll G, Lüscher TF.

J Hypertens Suppl. 1999 Feb;17(1):S25-35. Review.

PMID:
10340841
14.

Effects of valsartan or amlodipine on endothelial function and oxidative stress after one year follow-up in patients with essential hypertension.

Hirooka Y, Kimura Y, Sagara Y, Ito K, Sunagawa K.

Clin Exp Hypertens. 2008 Apr;30(3):267-76. doi: 10.1080/10641960802071000.

PMID:
18425706
15.

Beneficial effect of T-type calcium channel blockers on endothelial function in patients with essential hypertension.

Oshima T, Ozono R, Yano Y, Higashi Y, Teragawa H, Miho N, Ishida T, Ishida M, Yoshizumi M, Kambe M.

Hypertens Res. 2005 Nov;28(11):889-94.

PMID:
16555577
16.

Vascular protection: current possibilities and future perspectives.

Lüscher TF.

Int J Clin Pract Suppl. 2001 Jan;(117):3-6. Review.

PMID:
11715356
17.

The vascular endothelium in hypertension.

Spieker LE, Flammer AJ, Lüscher TF.

Handb Exp Pharmacol. 2006;(176 Pt 2):249-83. Review.

PMID:
16999229
18.

Antihypertensive drugs and reversing of endothelial dysfunction in hypertension.

Taddei S, Virdis A, Ghiadoni L, Sudano I, Salvetti A.

Curr Hypertens Rep. 2000 Feb;2(1):64-70. Review.

PMID:
10981130
19.

[Calcium antagonists: current and future applications based on new evidence. Pleiotropic effects of calcium channel blockers on vascular endothelial function].

Morimoto Y, Kureishi-Bando Y, Murohara T.

Clin Calcium. 2010 Jan;20(1):69-75. doi: CliCa10016975. Review. Japanese.

PMID:
20048436
20.

Coronary benefits of calcium antagonist therapy for patients with hypertension.

Motro M, Shemesh J, Grossman E.

Curr Opin Cardiol. 2001 Nov;16(6):349-55. Review.

PMID:
11704704

Supplemental Content

Support Center